Prostate-specific antigen and prostate cancer prognosis

Journal of the National Cancer Institute

Volumn 98, Issue 21, 2006, Pages 1509-1510

  Church, Timothy R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EDITORIAL; FOLLOW UP; HUMAN; MATHEMATICAL MODEL; MORBIDITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SAMPLE SIZE; VALIDITY;

HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN;

EID: 33750578041     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj455     Document Type: Editorial

References (4)

1. Edwards W. N = 1: Diagnosis in unique cases. In Jacquez JA, editor. Computer diagnosis and diagnostic methods. Springfield (IL): Charles C. Thomas; 1972. p. 139-51.
2. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98: 1521-7.
3. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Control Clin Trials 2000;21: 251S-72S.
4. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90: 1817-23.